False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications [Technical note]
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The World Health Organization had endorsed Xpert® MTB/RIF (Xpert) as the initial diagnostic for multidrug-resistant tuberculosis (TB) or TB suspects co-infected with the human immunodeficiency virus. We investigated an unexpected case of rifampicin (RMP) resistance on Xpert using repeat Xpert, smear microscopy, MTBDRplus assay, culture, drug susceptibility testing, spoligotyping and rpoB gene sequencing. A false-positive result was most likely, given the wild type rpoB gene sequence and exclusion of both mixed infection and mixture of drug-susceptible and drug-resistant populations. When decentralising Xpert, test performance characteristics need to be understood by health care workers and methods of confirmation of RMP resistance need to be accessible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rapid Molecular Detection of Tuberculosis and Rifampin Resistance
Boehme, C. C., Nabeta, P., Hillemann, D., Nicol, M. P., Shenai, S., Krapp, F., Allen, J., Tahirli, R., Blakemore, R., Rustomjee, R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907847 · Cited by 2,309
Cited by
Lawn, S. D., Mwaba, P., Bates, M., Piatek, A., Alexander, H., Marais, B. J., Cuevas, L. E., McHugh, T. D., Zijenah, L., Kapata, N., et al. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70008-2 · Cited by 458
Practical Guidance for Clinical Microbiology Laboratories: Mycobacteria
Forbes, B. A., Hall, G. S., Miller, M. B., Novak, S. M., Rowlinson, M.-C., Salfinger, M., Somoskövi, A., Warshauer, D. M., & Wilson, M. L. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00038-17 · Cited by 311
Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF
Weyer, K., Mirzayev, F., Migliori, G. B., Van Gemert, W., D'Ambrosio, L., Zignol, M., Floyd, K., Centis, R., Cirillo, D. M., Tortoli, E., et al. (2013) · European Respiratory Journal · doi:10.1183/09031936.00157212 · Cited by 256
Evaluation of GeneXpert MTB/RIF for Diagnosis of Tuberculous Meningitis
Nhu, N. T. Q., Heemskerk, D., Thu, D. D. A., Chau, T. T. H., Mai, N. T. H., Nghia, H. D. T., Loc, P. P., Ha, D. T. M., Merson, L., Thinh, T. T. V., et al. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.01834-13 · Cited by 244
“However, rare false-positive results for rifampin resistance have been reported with Xpert (40), and the consequences of mistakenly treating a patient with rifampin-susceptible TBM with weak second-line regimens would be grave.”
BackgroundSohn, H., Aero, A. D., Menzies, D., Behr, M., Schwartzman, K., Alvarez, G. G., Dan, A., McIntosh, F., Pai, M., & Denkinger, C. M. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu022 · Cited by 95
Metadata
- Authors
- Van Rie, A., Mellet, K., John, M.-A., Scott, L., Page-Shipp, L., Dansey, H., Victor, T., & Warren, R.
- Venue
- The International Journal of Tuberculosis and Lung Disease
- Published
- 2012-02-01
- Volume
- 16
- Issue
- 2
- Pages
- 206-208
- ISSN
- 1027-3719 (ISSN-L)
- OpenAlex
- W2163683100
- Cited by
- 73
- References
- 1
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications [Technical note]. https://app.cochat.ai/papers/10.5588/ijtld.11.0395
- The paper
- Van Rie, A., Mellet, K., John, M.-A., Scott, L., Page-Shipp, L., Dansey, H., Victor, T., & Warren, R. (2012). False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications [Technical note]. The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.11.0395
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.